Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
Summary Background Tofacitinib is a Janus kinase inhibitor approved for the treatment of ulcerative colitis (UC). Aim To evaluate effectiveness, safety and use of tofacitinib in daily practice. Methods UC patients initiating tofacitinib were prospectively enrolled in 15 hospitals in the Netherlands. Corticosteroid‐free clinical remission (short clinical colitis activity index [SCCAI] ≤2), biochemical remission (faecal calprotectin level ≤250 µg/g), combined corticosteroid‐free clinical and biochemical remission, predictors of remission, safety outcomes, treatment dose and effect on lipids were... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2020 |
Reihe/Periodikum: | Alimentary Pharmacology & Therapeutics ; volume 51, issue 9, page 880-888 ; ISSN 0269-2813 1365-2036 |
Verlag/Hrsg.: |
Wiley
|
Schlagwörter: | Pharmacology (medical) / Gastroenterology / Hepatology |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26690625 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://dx.doi.org/10.1111/apt.15689 |